Your current location:HomeNewsReport

Unlock new skills | Emerson's two invention patents are certified

Recently, two liver cancer methylation markers invented by Emerson were authorized by the State Intellectual Property Office respectively, and obtained the invention patent certificate.

解锁新技能 | 艾米森两项发明专利获证

The liver cancer methylation markers provided by the patent have the advantages of high sensitivity and high specificity, and have good application prospects in the development of non-invasive detection products for liver cancer. Greater than 95% with greater than 80% specificity in cirrhosis samples. Up to now, Emerson has applied for nearly 60 patents. This certification marks another step forward for Emerson on the road of technology research and development and independent innovation!

my country is a big country with a high incidence of liver cancer. There are 855,000 new cases of primary liver cancer in the world each year, and 466,000 in China. There are 810,000 deaths due to primary liver cancer each year in the world, and there are 422,000 in China. The Outline of the 'Healthy China 2030' Plan clearly puts forward the goal of 'by 2030, the overall 5-year survival rate of cancer in my country will be increased by 15%'. In order to increase the proportion of early diagnosis of high-risk groups of hepatocellular carcinoma in my country, Amisen takes the lead in launching an early-stage liver cancer blood test product. This product has the characteristics of high sensitivity and high specificity, which can greatly improve the accuracy of early screening.

The detection of early-stage liver cancer by blood test has greatly improved the compliance of subjects, and can achieve accurate primary screening for the cancer diagnosis system, which greatly saves medical resources and improves the efficiency of diagnosis. In short, the introduction of blood testing can increase the proportion of early diagnosis of high-risk groups of liver cancer in my country and improve the happiness of the whole people.

Emerson liver cancer early detection product - Ai Xingan

解锁新技能 | 艾米森两项发明专利获证

Aixingan product features
  • Ultra-early stage: can detect early precancerous lesions

  • High accuracy: detection performance is better than protein markers

  • Extremely simple: only 2mL of plasma can be tested

  • High-throughput: using real-time quantitative PCR technology

  • No radiation: just take a venous blood sample

  • Excellent price: the cost of testing is much lower than that of NGS testing


This product is suitable for any of the following groups of men over the age of 35 and women over the age of 45:

  • Hepatitis B virus (HBV) and/or Hepatitis C virus (HCV)

  • infected population;

  • chronic alcoholism;

  • Patients with non-alcoholic fatty liver and liver cirrhosis caused by various reasons;

  • Long-term consumption of food contaminated with aflatoxin

  • schistosomiasis infection;

  • have a family history of liver cancer;

  • drug-induced liver damage

解锁新技能 | 艾米森两项发明专利获证

About Emerson Life Technology

Established in January 2015, Amisen Life Technology is a high-tech enterprise focusing on the research and development, registration, production and sales of early non-invasive detection products for high-incidence malignant tumors. Genetics, bioinformatics, clinical big data and artificial intelligence analysis have established a new generation of tumor screening and detection technology platform and screening product system, covering digestive system tumors, gynecological tumors, urinary system tumors and pan-cancer types. For malignant tumors, early, non-invasive and accurate detection of tumors is realized, and cancer is smothered in the bud.

Early tumor screening to defeat cancer

Emerson Life Technology, keep moving forward!

解锁新技能 | 艾米森两项发明专利获证


Related suggestion